This is due to non-operational losses, amounting to $3.5 million as compared to non-operational gains of $0.3 million in FY2022.
The group’s fair value loss on financial assets amounted to $1.74 million, due to the decrease in share prices of three other listed companies, Medinex, Singapore Paincare Holdings and Aoxin, with which it holds a direct interest of 22.66%, 3.31% and 0.34% respectively.
The directors are recommending a final dividend of 1 Singapore cents, subject to shareholders’ approval at the forthcoming Annual General Meeting to be convened.
Prior to this, the group has already paid an interim dividend of 1 Singapore cents per share in March 2023. In aggregate, the total dividend for FY2023 amounts to 2 Singapore cents per share.
See also: Keppel Pacific Oak US REIT’s 1QFY2025 distributable income falls by 19.3% y-o-y to US$9.6 mil
The group will have its first orthopaedic specialist joining in June 2023, which is “an important first step to broaden the spectrum of the group’s medical services”.
Shares in HCSS closed flat at 4.1 cents on Jul 27.
